Phase I/II study investigating safety and efficacy of adenovirus-specific T-cells given to high-risk paediatric patients post-HSCT to treat reactivation of ADV

Cell Medica and UCL Institute of Child Health Great Ormond Street Hospital for Children NHS Trust will undertake a Phase I/II clinical trial - ASPIRE (Adenovirus-Specific Paediatric Immune REconstitution). The study is designed to demonstrate the safety and efficacy of Cytovir ADV - Cell Medica’s adoptive cellular therapy for the treatment of adenovirus infections in paediatric patients following bone marrow transplant (allogeneic haematopoietic stem cell transplant or allo-HSCT).

Adenovirus infections cause mortality in up to 30% of children in high risk patient populations following allo-HSCT and current antiviral drug therapies are of limited benefit. Adoptive cellular therapy has already shown promising results in preventing viral disease in patients receiving a bone marrow transplant

Cell Medica will be study sponsor and will prepare their adenovirus specific T cell therapy products (Cytovir ADV) for patients being treated. Dr Waseem Qasim and Prof Bobby Gaspar of the UCL Institute of Child Health Great Ormond Street Hospital for Children NHS Trust are the study investigators.